A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.

medwireNews : The addition of immunotherapy to stereotactic ablative radiotherapy (SABR) significantly improves the event-free survival (EFS) of patients with treatment-naïve, early-stage or isolated parenchymal recurrent non-small-cell lung cancer (NSCLC), indicate phase 2 results.

The overall survival benefit offered by immune checkpoint inhibitors in people with advanced non-small-cell lung cancer varies by age, suggests a real-world study.

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

The addition of the anti-PD-1 agent serplulimab to chemotherapy significantly boosts the overall survival of treatment-naïve individuals with extensive-stage small-cell lung cancer, according to ASTRUM-005 trial results published in JAMA .

As a result of meeting predefined overall survival (OS) efficacy criteria, the phase 3 trial was stopped early on the recommendation of the independent data monitoring committee, report Miranda Gogishvili (University Clinic Ltd, Tbilisi, Georgia) and co-authors in Nature Medicine .

Supplementing first-line chemotherapy with the PD-1 inhibitor toripalimab significantly improves the progression-free survival and overall survival of patients with advanced non-small-cell lung cancer, suggest Chinese trial data.

The magnitude of survival benefit for patients who had CGP result-led treatments was insufficient to drive an overall survival gain for the entire tested population.

The addition of nivolumab to neoadjuvant chemotherapy significantly improves the progression-free survival and overall survival of individuals with resectable stage IIIA–B non-small-cell lung cancer, suggest data from NADIM II.

Among women with triple-negative breast cancer, the use of beta blockers may improve breast cancer-specific survival, suggests a population-based cohort study and meta-analysis.

We aimed to investigate the relationship between CD133 expression in colon cancer with prognostic factors and survival rate of patients with colon cancer by immunohistochemistry.

Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA / AKT1 / PTEN alterations, FAKTION data show.

PALOMA-2 study findings suggest that first-line palbociclib does not improve overall survival when added to letrozole for estrogen receptor-positive, HER2-negative advanced breast cancer, but the analysis was hindered by missing data.

Overall survival with first-line chemoimmunotherapy may be similar to that with immunotherapy alone among patients with advanced non-small-cell lung cancer and PD-L1 expression levels of at least 50%, pooled study data suggest.

Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, show data from the phase 3 ARASENS trial.

The active autologous dendritic cell-based immunotherapy DCVAC/PCa is well tolerated when combined with docetaxel plus prednisone but does not improve survival in men with metastatic castration-resistant prostate cancer, phase 3 study data show.

The team concludes: “Additional studies are needed to assess the association of cirAE management with survival outcomes and whether ICI therapy interruption or discontinuation in the setting of these toxic effects is clinically warranted or associated with overall survival.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group JAMA Dermatol 2022; doi:10.1001/jamadermatol.2021.5476

Truncating TP53 mutations are associated with shorter survival in people with localized non-small-cell lung cancer while mutations in KEAP1 are linked to poor outcomes in both localized and advanced disease, German researchers report.